© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Rebamipide didn’t just pop up overnight. Launched in the late twentieth century, Japanese scientists devoted years to searching for agents that could help protect and restore the stomach lining. Back then, ulcers and gastritis were sending far too many folks to the hospital, and not every treatment actually repaired tissue. Rebamipide’s development brought a shift—here came a compound meant to do more than just suppress acid. Researchers mapped out its unique potential to promote healing through stimulation of endogenous prostaglandins and mucus, thickening the stomach’s natural barrier. Its approval represented not just a pharmaceutical milestone, but a move towards therapy that focused on actual restoration, not just symptom suppression.
Pharmacies stock rebamipide mostly for oral use, put together as tablets. In many parts of Asia, doctors prescribe it for gastric ulcer, gastritis, or as an adjunct to nonsteroidal anti-inflammatory drugs (NSAIDs) to limit damage on stomach tissue. Unlike acid blockers, rebamipide stands apart because it’s not concerned about acid suppression—it’s all about helping the mucosa fight back. Hospitals and clinics saw fewer cases where chronic erosions wore away at patients, because of this restoration-first approach.
Rebamipide appears as a white crystalline powder, carrying a stable nature under proper storage. Most pharmacists and scientists recognize it by its sturdy molecular weight of 370.7 g/mol and its formula, C19H15ClN2O4. It hates dissolving in water but gets along better with organic solvents, which presents a challenge during formulation. This low solubility forced pharmaceutical scientists to develop thoughtful delivery methods, sharpening their skills in crafting bioavailable tablets for effective gut targeting.
In practice, rebamipide’s label carries clear dosage instructions, usually 100 mg three times daily for adults. Every package stresses keeping it away from children, storing at room temperature, and watching for allergies or rare side effects. Labels make it impossible to ignore what it treats and remind patients of possible reactions, like skin rash or digestive change. Pharmacists don’t skip patient education, letting folks know to keep it consistent, and not to expect it to work just like a painkiller or antacid.
Synthesizing rebamipide usually involves several organic chemical steps, starting with benzene derivatives and winding through reactions such as chlorination, cyclization, and amidation. Organic chemists know that slight tweaks in reaction temperature or solvent choice can swing yields in unpredictable ways, so process control matters. Looking back, these practical lessons pushed chemists to constantly update their playbooks, aiming for better yield and predictable purity. The focus has always been on limiting contaminants and ensuring the final product reaches medicine-grade standards fit for patients.
In the lab, rebamipide doesn’t just sit idle. It resists simple hydrolysis thanks to strong amide bonds but invites interest for possible analogs. Medicinal chemists experimented by swapping groups at the aromatic ring or tweaking the side chains, chasing improvements in mucosal protection or longer-acting formulations. Some of these explorations faded, as modified compounds did not always show better results in clinical testing. Still, each experiment with its structure taught the field more about how the gut’s healing machinery works and what molecular features really matter for tissue regeneration.
Doctors and researchers sometimes get lost in the sea of drug names. Rebamipide may appear under its generic name or by branded names in different countries, but the essence stays unchanged. As patents changed hands globally, new names popped up for regional markets, driven more by marketing than by science. Yet, regardless of synonym, the recognition sits squarely with rebamipide’s role as a mucosal protectant, trusted for decades in places where GI distress drives up hospital admissions.
Safety isn’t just a checklist; it means real consequences for real people. Clinical studies observed rare but possible side effects—skin rashes, liver enzyme changes, and infrequent hypersensitivity reactions. Facilities where rebamipide gets manufactured keep everything monitored, from air quality in labs to cross-checks against contamination. During tablet formulation, machine calibration and environmental controls turn into standard procedure—not just to please regulators but because any slip means risk for patients who rely on this therapy. Familiar protocols like wearing gloves, masks, and precision weighing aren’t optional; they are drilled into lab culture from early training.
Clinicians use rebamipide when NSAIDs start causing ulcers or for patients who can’t handle traditional proton pump inhibitors. Hospital records show fewer ulcer recurrences in people who stuck with their course, compared to those who only managed symptoms. Across Asia, doctors added rebamipide to treatment protocols for Helicobacter pylori eradication, seeking to repair gastric lining faster and reduce inflammation lasting beyond infection. Some early experiments even eyed its use in mouth ulcer healing, though results varied a lot across populations.
Drug developers push rebamipide further, teaming up across borders to expand its reach. Labs in Europe and the US dabbled with new oral suspensions and eyedrops, hoping its healing qualities carry over to dry eye treatments or mucosal injuries outside the gut. R&D teams sift through clinical trial data, watching efficacy graphs while balancing safety profiles against emerging competition. Pharma firms haven’t ignored how slow release formulations may keep drug levels steadier, helping patients with chronic gastric irritation stick to their regimens without sharp peaks and valleys in symptoms.
Toxicologists never overlook the basics. Animal tests flagged that rebamipide stays remarkably well-tolerated at regular doses, with only high exposures leading to issues like weight loss or organ stress. Long-term surveillance uncovered no signs of carcinogenicity or cumulative toxicity, supporting safer long-term prescriptions. Trials in humans rarely logged dangerous reactions outside of isolated allergies. Yet, medical teams keep up monitoring because a spotless record in the early years never rules out strange responses from rare genetic backgrounds or drug interactions later on.
The future for rebamipide doesn’t sit in the hands of chemistry alone. Growing problems like increasing NSAID use, aging populations, and a rise in chronic gastritis keep physicians interested in therapies that do more than tamp down stomach acid. Drug designers talk about new delivery systems—think fast-acting films, modified-release capsules, or even topical gels for oral wounds. Researchers still debate optimal mixtures for patients with complex health profiles, aiming to personalize regimens instead of offering a one-size-fits-all schedule. Decisions will lean on fresh evidence, not just the drug’s legacy. Every success or failure in this process brings the field a step closer to treating GI injury with more precision, less guesswork, and a stronger foundation in science that cares as much for healing as for relieving pain.
Rebamipide caught my eye years ago as a medicine making waves in Japan long before it landed on pharmacy shelves elsewhere. Doctors started talking about it because it can help people with stomach or gut troubles, and that’s a big deal. More people than you’d think look for relief from ulcers or nagging stomach inflammation. Rebamipide fills that gap.
Not every pill helps your stomach lining recover. Rebamipide works differently than those acid blockers that crowd medicine cabinets. It encourages the body to create more mucus around the stomach, providing a layer of natural protection. It also boosts blood supply to tissues, letting them heal quicker. That reminds me of how a good rain after a drought brings parched plants back to life.
Most folks might not get excited about “gastroprotection,” a term on medical websites, but if you’ve been stuck with the burning gnaw of an ulcer, you understand why it matters. Rebamipide shines for people using nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, which can eat away at that gut lining. Many elderly folks and patients with lingering pain rely on these painkillers and then get stuck in a cycle of stomach problems. Rebamipide helps them keep taking the medication they need without trashing their stomach.
Doctors in some countries prescribe rebamipide alongside NSAIDs to prevent stomach bleeding. This wasn’t just a stab in the dark. Clinical trials show rebamipide reduces ulcer formation in these patients. Years of studies back up its safety profile, so doctors can trust it for longer-term therapy. That’s important, because some patients never stop needing NSAIDs.
Still, the story doesn’t stop at ulcers. People with chronic gastritis or even mouth ulcers benefit, too. I know someone who struggled with dry, painful mouth ulcers, and after starting rebamipide, the sores became less frequent. This medicine works its calming touch in other spots, because its main trick is helping tissue heal itself—not just masking pain or shutting off acid.
Some researchers explore rebamipide for gut-related immune disorders or after injury from radiation. They’re looking for safe solutions when standard care isn’t enough. Though evidence needs to grow stronger in these new uses, rebamipide’s track record draws attention. It usually causes mild side effects, like constipation or bloating, which most folks can live with if it means better healing.
With all the hype around new drugs, people forget about generics and time-tested medicines that improve daily life for thousands. Rebamipide slides under the radar but deserves more attention, especially in clinics outside Asia. It doesn’t suit every person with stomach pain. Long-term use or mixing with other medicines needs a doctor’s eye. But for those stuck in a tough situation—a need for NSAIDs, a stubborn ulcer—rebamipide sits as a solid, medically grounded option.
Gut health shapes how folks eat, move, and sleep. Medicines like rebamipide, supported by decades of use and research, help more than the textbooks show. Giving people safe healing, not just symptom cover-ups, should always be the goal.
Many people dealing with stomach discomfort or ulcers will hear about rebamipide from their doctor. Rebamipide isn’t just another tablet you pop on a whim; it has a clear job. Physicians use it for patients with conditions like gastritis and ulcers because studies show it helps protect and repair the stomach lining. The value of proper guidance is often overlooked. Patients sometimes change their schedule or skip doses, hoping that their bodies will “figure things out.” That’s not how stomach medicine works.
Doctors usually recommend taking rebamipide three times a day. It’s not an accident. Research shows that splitting up the dose keeps the active ingredient at stable levels, which gives the stomach steady protection. People sometimes ask if it’s fine to take it just once or twice for convenience. Cutting corners often leads to weaker results. Ulcer patients who skip doses or space them too far apart may feel like they’re saving time, but the weakened protection shows up in persistent symptoms or slower healing.
Eating just before or right after taking rebamipide can change how much the body absorbs. In everyday practice, doctors tend to suggest taking it after meals. This cuts down the risk of mild stomach upset and reflects what’s worked for thousands of cases. I’ve talked with people who thought they could mix it in with their usual lunch or dinner routine. A little care with scheduling works better. Consistency isn’t just a matter of habit; it’s a proven way to help the gut heal.
We all forget to take pills sometimes. Missing a dose of rebamipide can be frustrating, but doubling up on the next dose isn’t the answer. That can lead to side effects like diarrhea or a jittery stomach, which no one wants. If a dose is forgotten, just take it as soon as you remember – unless it’s almost time for the next dose. In that case, carry on as planned. The body benefits from steady levels, not sudden spikes.
Rebamipide sometimes gets prescribed for other conditions like dry mouth in cancer patients. Doctors monitor progress closely. There are reasons for this. Stomach medicine isn’t trivial – it ties in with diet, stress, other medicines, and lifestyle changes like quitting smoking or cutting back on painkillers. I’ve seen stubborn ulcers finally get better after both proper dosing and a few steady tweaks in habits. That improvement matters much more than any miracle claim from a bottle.
Many people want to learn about medicine from friends or the internet. That feels tempting, especially with something as common as stomach pain. Reliable information should come from people trained in the details – pharmacists and doctors, not just message boards or word of mouth. Patients who stick with professional guidance end up with better outcomes and fewer surprises. Solid advice always wins over shortcuts or guesswork.
Simple steps help patients stay on track. Setting phone reminders or keeping tablets in a spot that’s hard to miss can help people stay consistent. Always ask the pharmacist any questions about side effects or meal timing. Never blend new over-the-counter drugs or herbal products without telling a doctor. Health is built on day-to-day decisions, not one-off heroic actions.
Many people dealing with stomach ulcers and gastritis have come across Rebamipide at some point during their treatment. This medication promotes healing in the stomach lining, and some doctors prescribe it to manage chronic gastritis or injury caused by anti-inflammatory medications. The drug helps many, but it makes sense to talk about what happens to those who take it—especially the common side effects that show up in day-to-day life.
Rebamipide targets the gut, so most side effects hit there first. Expect occasional abdominal discomfort—stuff like bloating, mild stomach pain, or loose stools. In some studies, between five and ten people out of every hundred noticed nausea or felt a bit queasy in the first few days. Diarrhea has made an appearance for some, along with constipation, though these cases usually stay mild. People often report these stomach complaints fading as their bodies adjust.
A few folks get itchy or notice a rash. On rare occasions, swelling or redness appears. Allergy-like symptoms rarely move beyond minor skin issues, but if lips or the face swell, medical attention becomes urgent. I’ve seen patients develop redness on the arms or trunk that went away once they stopped the medication. If someone already struggles with allergies, regular monitoring can help catch problems quickly.
Fatigue creeps up in some users. Feeling tired can make it tough to get through chores or work. I remember a neighbor having trouble staying alert after starting Rebamipide, forcing him to switch his morning schedule. Drowsiness doesn’t hit everyone, but it ranks among the common complaints that lead people to bring up their concerns at follow-up appointments. Keeping hydrated and moving around during the day can lessen that sleepy feeling for some patients.
Taste changes are less common but still worth mentioning. Some people tell their doctors about experiencing a metallic taste, or finding foods suddenly bland. I’ve heard similar feedback from friends using acid-reducing medication, though it seems less persistent with Rebamipide. Changes in appetite or finding less enjoyment in meals can linger, so having regular feedback with a health team is essential.
Liver function changes crop up in a very small group. Mild elevation in liver enzymes sometimes turns up in routine blood work. Keeping tabs on symptoms like jaundice or darker urine gives peace of mind, but true liver problems from Rebamipide remain rare in medical literature. Some patients struggle with mild headaches or dizziness. In my clinic, combining the medication with regular monitoring and encouraging honest conversations about symptoms has improved long-term treatment experiences.
Doctors usually encourage folks to check in if any side effect feels out of hand or drags on. Reading the package insert matters, but no handout matches a candid talk with a trusted physician. Rebamipide offers real help for stomach healing, but symptoms like persistent abdominal pain, unexplained rashes, or feelings of drowsiness shouldn’t be brushed off. Everyone’s body responds differently—open communication, routine blood checks, and awareness of any bodily changes support a safer journey with this medication. Simple, honest conversations go a long way in catching tricky side effects before they cause long-term trouble.
Expecting mothers worry about every pill they’re asked to take. Rebamipide, a medication used for ulcers and gut troubles, lands on that list of concerns. Anyone who’s been pregnant knows how every choice can feel heavy. The safety data for rebamipide in pregnancy and during breastfeeding remain pretty limited. Extensive testing on its use among pregnant people just hasn’t happened. Most of the available research comes from animal studies, and doctors understand that human outcomes can differ a lot.
Rebamipide works by protecting the stomach lining and fighting inflammation, which sounds helpful in theory. But time and again, the FDA and global regulators agree: animal studies don’t guarantee how a drug acts in real pregnancies. In those animal tests, rebamipide hasn’t caused birth defects at typical doses, but that doesn’t answer every question. The lack of human data keeps doctors cautious. Most guidelines suggest avoiding this medication in pregnancy if safer options exist.
Some ulcer drugs like proton pump inhibitors and H2 blockers come with more proven safety records. Decades of use mean doctors and parents know what to expect. Rebamipide came to market later and doesn’t have that kind of track record. Pharmacists will tell you, information about how much rebamipide passes into breast milk just isn’t available. That gap leaves a big question mark for breastfeeding mothers. The gut often stays calm enough during pregnancy with less aggressive medications, and many providers stick to what’s familiar.
Any medication brings its own set of trade-offs. I remember a friend, early in her pregnancy, who felt torn between taking prescribed drugs and risking symptom flare-ups. The stress itself did her no favors. Clinicians often weigh the seriousness of a mother's stomach issues against the unknowns of the drug. Ulcers causing major bleeding or pain might leave fewer choices on the table, but for mild cases, most professionals stick with agents they trust more. They go back to basics: non-drug remedies, safer drugs, and extra monitoring.
Open conversations make the biggest difference. Many women don’t feel comfortable asking their providers questions about medications, but nobody should swallow a pill without understanding the risks. Protecting a child starts with asking difficult questions, even if the answer is “We don’t know.” The best doctors provide the evidence and let the person decide, with support and discussion along the way.
Too few medications get rigorously studied in pregnant or breastfeeding individuals. It’s a gap that affects millions. Pregnant bodies change how drugs are absorbed and processed, so relying on animal research alone cuts corners. The answer lies in safe, carefully monitored studies involving people who are actually pregnant or nursing. Research funding for maternal and fetal medicine supports healthier futures.
Anyone considering rebamipide during pregnancy or while breastfeeding benefits from honest, supportive dialogue with their healthcare professional. Until more clinical information comes to light, most experts recommend taking another route if effective alternatives exist. Facing uncertainty about medications adds stress, but knowledge and teamwork help families make the best decisions for themselves.
Sitting at a crowded pharmacy, juggling prescriptions, it’s easy to overlook how one pill might mingle with another. Take rebamipide, for example. Doctors often use it for stomach problems, especially to help heal ulcers or soothe gastritis. Blister packs promise relief, but they don’t always warn about mixing with other drugs you may rely on for diabetes, blood pressure, or pain relief. Ignoring these interactions can turn a simple treatment into a bigger health problem.
Rebamipide targets inflammation and helps repair the lining inside the stomach and gut. It doesn’t affect the acid itself the way drugs like omeprazole do; instead, it gets in there and boosts healing agents, including prostaglandins, and reduces harmful oxygen radicals. The way your body processes rebamipide mostly happens in the liver, through enzymes. This means certain medications, especially those relying on the same liver pathways, may tangle with rebamipide, either boosting its effect or blunting it.
While rebamipide tends to keep to itself, living proof from clinics and studies shows that combinations can get tricky. For instance, antibiotics such as clarithromycin and levofloxacin, sometimes paired to attack stubborn ulcers, might toss in their own side effects or strain your liver when thrown together with rebamipide. Blood-thinners like warfarin, beloved by many heart patients, count on a stable stomach—bring in rebamipide, and there’s a chance for subtle shifts that can either reduce or enhance warfarin’s power, making it harder to manage bleeding risks.
A friend of mine on NSAIDs for chronic pain needed stomach protection, so she started rebamipide. She felt better but skipped mentioning her diabetes medications. Later, she noticed her blood sugar control changed. Even though research says rebamipide’s direct interaction with anti-diabetic drugs isn’t common, real-life bodies aren’t controlled lab settings. Food, age, underlying conditions, genetics—all these wild cards can tip the scales unexpectedly.
Most pharmacies carry printed lists, and plenty of online databases highlight possible drug-to-drug problems, but they don’t always reflect actual experience. Many folks keep separate stashes of medications at home, visiting different clinics. Tracking everything seems exhausting. Yet bringing every pill, supplement, and herb to check-ups can head off problems. A quick review with your pharmacist or doctor—especially after adding or switching meds—can flag issues in advance.
Healthcare pros can use electronic health record alerts to spot interactions before the prescription hits your hands. Patients get the best results by taking an active role, reading the flyers that come with medications, and asking blunt questions about what to watch. Community education programs can bridge the knowledge gap and give patients the tools to ask better questions.
According to the FDA and published studies in journals such as Clinical Drug Investigation, rebamipide rarely causes major interactions compared to heavy-hitters like anticoagulants or antidepressants. But rare isn’t never. The more medications a person takes, the higher the odds something unpredictable sneaks in, especially for older adults with multiple health issues.
Drug interactions don’t stay fixed. New research, changing health, and even what you eat can shift the balance. Staying open with your healthcare team about every pill in your lineup—prescribed, over-the-counter, or herbal—makes a world of difference in keeping treatments safe and effective.
| Names | |
| Preferred IUPAC name | 2-(4-chlorobenzoylamino)-3-(2-oxo-1H-quinolin-4-yl)propanoic acid |
| Other names |
Rebanex Mucosta Acidcare Rebamity Rema |
| Pronunciation | /riːˈbamɪpaɪd/ |
| Identifiers | |
| CAS Number | 112811-59-3 |
| Beilstein Reference | 157187 |
| ChEBI | CHEBI:87100 |
| ChEMBL | CHEMBL1627 |
| ChemSpider | 119360 |
| DrugBank | DB01181 |
| ECHA InfoCard | echa.europa.eu/infocard/100045944-18 |
| EC Number | 4.2.1.126 |
| Gmelin Reference | 128838 |
| KEGG | D01965 |
| MeSH | D018980 |
| PubChem CID | 54111 |
| RTECS number | FF3ZCQ8E1V |
| UNII | 8Y164V895Y |
| UN number | UN number not assigned |
| CompTox Dashboard (EPA) | DTXSID9020806 |
| Properties | |
| Chemical formula | C19H15ClN2O4 |
| Molar mass | 370.39 g/mol |
| Appearance | White to pale yellow crystalline powder |
| Odor | Odorless |
| Density | 1.295 g/cm³ |
| Solubility in water | Insoluble in water |
| log P | 0.44 |
| Vapor pressure | 3.49E-19 mmHg |
| Acidity (pKa) | 3.42 |
| Basicity (pKb) | 11.86 |
| Magnetic susceptibility (χ) | -44.5×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.663 |
| Viscosity | Viscous liquid |
| Dipole moment | 3.45 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 354.8 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -312.4 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -4678 kJ/mol |
| Pharmacology | |
| ATC code | A02BX14 |
| Hazards | |
| Main hazards | May cause gastrointestinal disturbances, hypersensitivity reactions, and liver function abnormalities. |
| GHS labelling | No GHS labelling. |
| Pictograms | oral administration, prescription only, tablets, antiulcer agent |
| Signal word | No signal word |
| Hazard statements | No hazard statements. |
| Precautionary statements | Keep out of reach of children. If you experience any unusual symptoms or allergic reactions, discontinue use and consult your physician. Use only as directed by your healthcare provider. |
| NFPA 704 (fire diamond) | Health: 1, Flammability: 1, Instability: 0, Special: – |
| Flash point | > 349.1 °C |
| Lethal dose or concentration | LD50 (rat, oral): >1000 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Rebamipide: ">5000 mg/kg (oral, rat) |
| NIOSH | Not Identified |
| PEL (Permissible) | Not Established |
| REL (Recommended) | 100 mg |
| IDLH (Immediate danger) | Not listed |
| Related compounds | |
| Related compounds |
Quinoline Afloqualone |
